Fundamental And Clinical Evaluation of 9,3”-Diacetylmidecamycin in Pediatric Field

Yukio Iwasaki, Satoshi Iwata, Takefumi Kanemitsu, Keiji Jozaki, Haruki Hattori, Ryoh Wakabayashi, Yoshibumi Kojima, Keisuke Sunakawa, Tadao Oikawa, Mitsuru Osano, Yasuo Ichihashi

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

1. The dry syrup of MOM was administered orally to 17 patients mainly with heart deseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases,the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20mg/kg treatment.The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3cases. 7. Any pediatric patient did not refuse taking.

Original languageEnglish
Pages (from-to)429-437
Number of pages9
Journalthe japanese journal of antibiotics
Volume35
Issue number2
DOIs
Publication statusPublished - 1982 Jan 1

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Fundamental And Clinical Evaluation of 9,3”-Diacetylmidecamycin in Pediatric Field'. Together they form a unique fingerprint.

Cite this